ClinicalTrials.gg
CompletedNCT03822078Updated Jul 24, 2019Results posted

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women

A Phase 1 interventional study of Placebo and Denosumab in Osteoporosis, sponsored by Amgen. Completed. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 15 years 3 months after the study started (first participant enrolled Sep 2003, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
40th of 64
45 · median 90
Started
2003
the only one that year
Phase 1
5 of 64
none open now
Registered
41st of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 40th largest by enrollment, is the only one that started in 2003, is one of 5 in phase 1, and was the 41st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The primary objective was to evaluate the safety and tolerability of denosumab (AMG 162) after a single subcutaneous administration in Japanese postmenopausal women.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • Postmenopausal
  • Denosumab
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ambulatory women between the ages of 40 and 64 years, inclusive
  • , defined as amenorrheic for at least 24 months
  • clinically acceptable physical exam
  • clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis) within normal limits or clinically acceptable to the investigator/sponsor at the time of screening with the exception of (AST) and alkaline phosphatase (ALT), which must be \< 1.25 times the , or gamma-glutamyl transpeptidase (GGT), which must be \< 1.5 times the upper limit of normal
  • normal or clinically acceptable (ECG) (12-lead reporting ventricular rate and PR, QRS, , and QTc intervals)
  • between 17 and 27
  • willing to sign an approved form before any study-specific assessments and oral consultations are performed

Exclusion criteria

Exclusion Criteria:

  • administration of medications within 6 months before product administration that are known to effect bone metabolism, including but not limited to the following: calcitonin, parathyroid hormone (or any derivative), supplemental vitamin D (> 1000 IU/day), glucocorticosteroids (inhaled or topical administered more than 2 weeks before the date of were allowed), anabolic steroids, calcitriol and available analogues, diuretics
  • administration of the following medications within 12 months before study drug administration: bisphosphonates, fluoride for osteoporosis
  • diagnosed with any condition that affects bone metabolism
  • greatly differing levels of physical activity compared with the 6 months before investigational product administration or constant levels of intense physical activities
  • routine alcohol intake of ≥ 2 drinks/day, on average, within 6 months of investigational product administration
  • known sensitivity to any drugs
  • positive test results for surface antigen, virus, antigen/antibody, syphilis
  • receiving or received any investigational drug (or was currently using an investigational device) within 4 months before receiving investigational product
  • donated any amount of blood within 16 weeks, or over 400 mL (Note: not 400 mL but 200 mL, for the subjects who were to be enrolled into cohorts 4 or 5) within 1 year of the start day of screening
  • subject had previously entered this study
  • any other condition that might have reduced the chance of obtaining data (eg, known poor compliance) required by the protocol or that might have compromised the ability to give truly informed consent
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received a single subcutaneous injection of placebo to denosumab on day 1.

    Drug: Placebo

  • Experimental
    Denosumab

    Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.

    Biological: Denosumab

Interventions

  • DrugPlacebo

    Administered by subcutaneous injection

  • BiologicalDenosumab

    Administered by subcutaneous injection

    Also known as: AMG 162, Prolia

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: From day 1 up to 4 months for participants assigned to the 0.03 or 0.1 mg/kg dose cohorts, up to 6 months for participants assigned to the 0.3 mg/kg dose cohort and for up to 9 months for participants assigned to the 1.0 or 3.0 mg/kg dose cohorts

Secondary outcomes

  1. Area Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab

    Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts

  2. Maximum Observed Concentration of Denosumab (Cmax)

    Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts

  3. Time to Maximum Observed Concentration (Tmax) of Denosumab

    Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts

  4. Apparent Clearance (CL/F) of Denosumab

    Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts

  5. Mean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration

    Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts

  6. Percent Change From Baseline in Urinary N-Telopeptide Corrected for Urine Creatinine (N-Tx/Cr)

    Time frame: Baseline and day 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only).

  7. Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP)

    Time frame: Baseline and day 8, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, and 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only)

  8. Percent Change From Baseline in Intact Parathyroid Hormone (iPTH)

    Time frame: Baseline and day 2, 3, 5, 8, 15, 29, 57, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only)

07

Results

Posted Jul 24, 2019

Participant flow

This study was conducted at one clinical center in Japan.

Participant flow — Overall Study
MilestonePlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Started1266876
Received study drug1066666
Completed1066666
Not completed200210

Outcome measures

PrimaryNumber of Participants With Adverse Events
Time frame:
From day 1 up to 4 months for participants assigned to the 0.03 or 0.1 mg/kg dose cohorts, up to 6 months for participants assigned to the 0.3 mg/kg dose cohort and for up to 9 months for participants assigned to the 1.0 or 3.0 mg/kg dose cohorts
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Any adverse event623565
Serious adverse events000000
Treatment-related adverse events401344
Discontinuation due to adverse events000000
Deaths on study000000
SecondaryArea Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab
Time frame:
Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Reported as:
Mean · μg*day/mL
Area Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab
μg*day/mLDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Area Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab2.06 ± 0.5315.2 ± 6.784.3 ± 20.1481 ± 1311790 ± 650
SecondaryMaximum Observed Concentration of Denosumab (Cmax)
Time frame:
Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Reported as:
Mean · ng/mL
Maximum Observed Concentration of Denosumab (Cmax)
ng/mLDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Maximum Observed Concentration of Denosumab (Cmax)99.6 ± 25.8492 ± 1661910 ± 6588690 ± 217027400 ± 7880
SecondaryTime to Maximum Observed Concentration (Tmax) of Denosumab
Time frame:
Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Reported as:
Median · days
Time to Maximum Observed Concentration (Tmax) of Denosumab
daysDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Time to Maximum Observed Concentration (Tmax) of Denosumab7.0 (7 to 10)12.0 (7 to 21)14.0 (7 to 21)14.0 (10 to 21)14.0 (14 to 42)
SecondaryApparent Clearance (CL/F) of Denosumab
Time frame:
Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Reported as:
Mean · mL/day/kg
Apparent Clearance (CL/F) of Denosumab
mL/day/kgDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Apparent Clearance (CL/F) of Denosumab15.3 ± 4.28.31 ± 4.973.72 ± 0.892.20 ± 0.561.85 ± 0.58
SecondaryMean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration
Time frame:
Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Reported as:
Mean · days
Mean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration
daysDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Mean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration15.5 ± 4.722.5 ± 3.933.6 ± 5.842.6 ± 7.051.4 ± 5.8
SecondaryPercent Change From Baseline in Urinary N-Telopeptide Corrected for Urine Creatinine (N-Tx/Cr)
Time frame:
Baseline and day 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only).
Reported as:
Mean · percent change
Percent Change From Baseline in Urinary N-Telopeptide Corrected for Urine Creatinine (N-Tx/Cr)
percent changePlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Day 212 ± 116 ± 4-25 ± 8-22 ± 11-40 ± 7-64 ± 4
Day 319 ± 5-6 ± 7-30 ± 5-40 ± 11-51 ± 8-60 ± 3
Day 47 ± 6-18 ± 9-37 ± 16-48 ± 11-55 ± 6-62 ± 5
Day 523 ± 10-12 ± 12-44 ± 5-51 ± 8-53 ± 8-66 ± 6
Day 69 ± 7-1 ± 18-53 ± 8-62 ± 7-59 ± 6-72 ± 4
Day 816 ± 7-12 ± 13-55 ± 7-64 ± 5-57 ± 7-64 ± 10
Day 113 ± 8-36 ± 5-67 ± 5-65 ± 7-69 ± 6-79 ± 3
Day 154 ± 3-51 ± 4-68 ± 4-71 ± 5-71 ± 5-77 ± 5
Day 22-1 ± 5-41 ± 4-71 ± 6-70 ± 7-70 ± 5-82 ± 3
Day 29-1 ± 5-39 ± 5-68 ± 3-67 ± 6-64 ± 7-77 ± 4
Day 43-1 ± 5-33 ± 6-67 ± 4-68 ± 7-69 ± 8-81 ± 4
Day 570 ± 8-14 ± 3-59 ± 6-64 ± 8-56 ± 10-79 ± 6
Day 71-5 ± 7-23 ± 6-48 ± 10-65 ± 6-68 ± 5-82 ± 3
Day 858 ± 74 ± 8-48 ± 12-58 ± 9-68 ± 4-83 ± 4
Day 991 ± 64 ± 6-37 ± 15-64 ± 5-72 ± 4-77 ± 10
Day 113-5 ± 63 ± 4-30 ± 15-53 ± 10-77 ± 3-84 ± 2
Day 141-7 ± 9——-51 ± 5-62 ± 5-81 ± 3
Day 169-15 ± 6—6 ± 14-41 ± 11-48 ± 9-78 ± 5
Day 197-3 ± 5———-47 ± 8-79 ± 4
Day 225-7 ± 11—42.0-30 ± 4-20 ± 17-70 ± 4
Day 253-13 ± 10———-25 ± 14-62 ± 5
Day 281———-13 ± 8——
Day 309————-19 ± 13-23 ± 12
SecondaryPercent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP)
Time frame:
Baseline and day 8, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, and 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only)
Reported as:
Mean · percent change
Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP)
percent changePlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Day 8-0.4 ± 2.8-6.9 ± 5.916.6 ± 4.77.1 ± 2.0-0.5 ± 5.13.1 ± 6.4
Day 15-2.1 ± 1.41.1 ± 3.18.6 ± 2.013.2 ± 2.05.6 ± 5.911.5 ± 7.8
Day 221.1 ± 2.812.7 ± 3.15.8 ± 2.37.8 ± 3.87.0 ± 5.39.7 ± 5.8
Day 295.3 ± 2.98.9 ± 3.611.0 ± 3.5-0.7 ± 2.85.8 ± 4.2-0.4 ± 4.5
Day 433.6 ± 3.1-2.3 ± 2.8-7.6 ± 4.3-20.3 ± 3.2-10.2 ± 4.0-14.7 ± 2.6
Day 572.7 ± 1.6-5.9 ± 5.1-19.2 ± 2.8-33.1 ± 3.1-21.0 ± 4.9-24.0 ± 2.6
Day 71-0.9 ± 3.0-5.5 ± 4.8-29.0 ± 5.7-41.0 ± 2.2-36.1 ± 5.2-33.9 ± 4.7
Day 851.3 ± 2.2-7.9 ± 6.3-27.2 ± 6.1-47.7 ± 3.2-42.1 ± 4.2-43.9 ± 1.9
Day 991.7 ± 3.2-13.1 ± 3.3-33.4 ± 5.5-49.4 ± 3.0-44.0 ± 5.5-47.5 ± 2.7
Day 1133.1 ± 2.3-0.5 ± 7.1-32.6 ± 5.4-54.2 ± 2.6-49.7 ± 5.1-51.4 ± 2.6
Day 141-0.2 ± 4.9——-57.2 ± 2.6-50.7 ± 6.9-52.9 ± 3.8
Day 1693.1 ± 4.3—-33.9 ± 7.8-52.9 ± 2.5-50.1 ± 4.6-53.7 ± 2.9
Day 1978.6 ± 5.8———-43.9 ± 8.6-52.5 ± 2.7
Day 2254.6 ± 3.0—19.5-37.1 ± 4.4-35.1 ± 8.5-48.4 ± 3.6
Day 25311.7 ± 6.5———-31.9 ± 9.7-44.0 ± 4.1
Day 281———-10.7 ± 6.1——
Day 309————-21.0 ± 14.7-26.8 ± 4.8
SecondaryPercent Change From Baseline in Intact Parathyroid Hormone (iPTH)
Time frame:
Baseline and day 2, 3, 5, 8, 15, 29, 57, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only)
Reported as:
Mean · percent change
Percent Change From Baseline in Intact Parathyroid Hormone (iPTH)
percent changePlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kg
Day 26.9 ± 8.72.4 ± 13.010.1 ± 14.144.0 ± 13.040.9 ± 19.5129.0 ± 25.2
Day 3-8.2 ± 6.128.9 ± 9.715.0 ± 18.871.7 ± 15.860.7 ± 21.7146.1 ± 46.0
Day 5-3.9 ± 6.047.6 ± 12.251.8 ± 17.9114.2 ± 27.2103.1 ± 41.8262.1 ± 61.9
Day 8-0.7 ± 8.937.7 ± 20.476.9 ± 20.7182.4 ± 40.2163.7 ± 38.4353.6 ± 92.4
Day 1511.2 ± 8.991.5 ± 8.2117.3 ± 33.4146.4 ± 29.0109.4 ± 36.3203.2 ± 27.2
Day 295.1 ± 7.797.2 ± 23.8110.9 ± 40.799.2 ± 16.870.4 ± 28.3215.2 ± 79.4
Day 575.3 ± 8.364.6 ± 18.4120.5 ± 35.598.0 ± 17.990.9 ± 20.8177.0 ± 36.8
Day 8517.1 ± 10.211.9 ± 9.636.6 ± 24.576.9 ± 20.264.4 ± 18.4170.5 ± 40.8
Day 995.6 ± 7.419.9 ± 10.546.4 ± 31.179.6 ± 13.944.0 ± 10.9178.5 ± 93.3
Day 113-1.2 ± 10.23.9 ± 15.429.5 ± 32.838.5 ± 13.546.5 ± 10.5155.7 ± 44.5
Day 141-3.8 ± 13.9——16.9 ± 11.122.8 ± 16.6175.4 ± 81.3
Day 169-7.9 ± 5.3—-16.7 ± 10.619.7 ± 8.221.9 ± 16.190.2 ± 27.6
Day 197-14.9 ± 5.4———17.0 ± 9.8100.7 ± 42.1
Day 225-5.1 ± 14.1—15.9-30.9 ± 5.06.2 ± 12.3151.4 ± 83.5
Day 2538.5 ± 12.6———10.9 ± 18.170.8 ± 31.5
Day 281———-26.1 ± 9.4——
Day 309————16.6 ± 24.933.8 ± 11.9

Adverse events

Collected over From day 1 up to 4 months for participants assigned to the 0.03 or 0.1 mg/kg dose cohorts, up to 6 months for participants assigned to the 0.3 mg/kg dose cohort and for up to 9 months for participants assigned to the 1.0 or 3.0 mg/kg dose cohorts.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/10 (0%)6/10 (60%)
Denosumab 0.03 mg/kg—0/6 (0%)2/6 (33.3%)
Denosumab 0.1 mg/kg—0/6 (0%)3/6 (50%)
Denosumab 0.3 mg/kg—0/6 (0%)5/6 (83.3%)
Denosumab 1.0 mg/kg—0/6 (0%)6/6 (100%)
Denosumab 3.0 mg/kg—0/6 (0%)5/6 (83.3%)
Denosumab Total—0/30 (0%)21/30 (70%)
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kgDenosumab Total
NASOPHARYNGITISInfections and infestations3/101/62/60/65/61/69/30
INJECTION SITE PAINGeneral disorders0/100/60/60/61/62/63/30
RHINORRHOEARespiratory, thoracic and mediastinal disorders0/100/60/61/62/60/63/30
ATRIAL FIBRILLATIONCardiac disorders0/100/61/60/60/60/61/30
SENSATION OF BLOCK IN EAREar and labyrinth disorders0/100/60/61/60/60/61/30
TINNITUSEar and labyrinth disorders1/100/60/61/60/60/61/30
BLEPHAROSPASMEye disorders0/100/60/60/60/61/61/30
CONJUNCTIVAL HAEMORRHAGEEye disorders0/100/60/61/60/60/61/30
CONJUNCTIVITISEye disorders0/100/60/60/60/61/61/30
ABDOMINAL PAINGastrointestinal disorders0/100/60/61/61/60/62/30

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)PlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kgTotal
Mean59.83 ± 2.8659.67 ± 2.3459.50 ± 3.3958.88 ± 3.8056.43 ± 3.9558.67 ± 2.3458.91 ± 3.22
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kgTotal
Female126687645
Male0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDenosumab 0.03 mg/kgDenosumab 0.1 mg/kgDenosumab 0.3 mg/kgDenosumab 1.0 mg/kgDenosumab 3.0 mg/kgTotal
Japanese126687645
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kumagai Y, Hasunuma T, Padhi D. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone. 2011 Nov;49(5):1101-7. doi: 10.1016/j.bone.2011.08.007. Epub 2011 Aug 12. PubMed 21871589 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2003 to primary completion in Dec 2004, 14 months.

Results were first posted in Jul 2019, 14 years 7 months after primary completion.

Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Jan 30, 2019
StartActual
Sep 30, 2003
Primary completionActual
Dec 24, 2004
CompletionActual
Dec 24, 2004
Results first posted
Jul 24, 2019
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03822078
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Sep 30, 2003
Primary completion
Dec 24, 2004
Completion
Dec 24, 2004
Results posted
Jul 24, 2019
Last update
Jul 24, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion